Drug intelligence / Profile preview

INB-400

Development stage: Phase 2
Lead developer: IN8bio
Modality: Cell Therapies
Administration: Intracranial (via Rickham Catheter)

Overview

INB-400 is an autologous gamma-delta T cell therapy product candidate genetically engineered to survive chemotherapy and maintain the natural ability to recognize, engage, and kill cancer cells. It is developed by IN8bio, Inc., and is primarily indicated for the treatment of glioblastoma. The therapy combines engineered, chemotherapy-resistant gamma-delta T cells with standard-of-care treatments to amplify immune signals and maximize tumor killing.

Other names: Autologous genetically modified gamma-delta T cellsDeltEx DRI

Targets

MICB (Major histocompatibility complex class i-related protein B)

Beyond the preview

Go deeper on INB-400.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INB-400.

Explore the full profile